Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan

Cancer Science

  ^{1    1    2    3    4    5    6    7    8    9    9    1,10} 

[1] Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan;Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan;Department of Gastroenterology, Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan;Department of Hematology, National Hospital Organization Disaster Medical Center, Tachikawa, Japan;Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan;Department of Hematology, Tochigi Cancer Center, Utsunomiya, Japan;Department of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan;Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan;Department of Oncology Clinical Development Planning, Ono Pharmaceutical, Osaka, Japan;Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi;

关键词: carfilzomib;    dexamethasone;    Japan;    lenalidomide;    multiple myeloma;   

DOI  :  10.1111/cas.13166

来源: publisher

【 摘 要 】

This is the first study in which the carfilzomib, lenalidomide and dexamethasone (KRd) regimen was evaluated in heavily pretreated multiple myeloma. This study is a multicenter, open‐label phase 1 study of KRd in Japanese patients with relapsed or refractory multiple myeloma (RRMM) patients. The objectives were to evaluate the safety, tolerability, efficacy and pharmacokinetics of the regimen. Carfilzomib was administrated intravenously over 10 min on days 1, 2, 8, 9, 15 and 16 of a 28‐day cycle. In cycle 1, the dosage for days 1 and 2 was 20 mg/m2, followed by 27 mg/m2. Lenalidomide and dexamethasone were administered at 25 mg (days 1–21) and 40 mg (days 1, 8, 15 and 22), respectively. Twenty‐six patients were enrolled. Patients had received a median of four prior regimens and 88.5% and 61.5% received previous bortezomib and lenalidomide, respectively. High‐risk cytogenetics were seen in 53.8% of patients. The overall response rate was 88.5%. A higher rate of hyperglycemia was observed than in a previous carfilzomib monotherapy study, but this was attributed to dexamethasone. Carfilzomib pharmacokinetics were not affected by lenalidomide and dexamethasone. The KRd regimen was well tolerated and showed efficacy in Japanese RRMM patients.

【 授权许可】

Unknown